EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective study

Seug Yun Yoon, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong-Won Lee, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-Won Cheong, Soo-Mee Bang, Joon Seong Park und 4 weitere

International Journal of Cancer · 2025-08 · 157 (3) · 526-533

DOI: 10.1002/ijc.35411 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Cancer, online erschienen am 15.03.2025. Verfasst von Seug Yun Yoon und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology & Medical Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea. Hauptthemen laut MEDLINE: Polycythemia Vera, Polyethylene Glycols, Interferon-alpha. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PharmaEssentia, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To prevent thrombosis in patients with polycythemia vera (PV), achieving a complete hematologic response (CHR) is highly recommended in practice. In addition, a reduced JAK2 V617F mutation burden is expected to have a disease‐modifying effect, and its molecular response (MR) is currently of significant interest. This study aimed to assess the association between CHR and MR in patients with PV following treatment with ropeginterferon alfa‐2b. This phase 2, single‐arm, open‐label, investigator‐initiated trial was conducted at 16 sites in South Korea. Ninety‐nine patients were treated with ropeginterferon alfa‐2b subcutaneously every 2 weeks, at doses of 250 μg (week 1), 350 μg (week 3), and 500 μg (week 5), until week 48. CHRs were 27% (25/94), 46% (40/87), 56% (47/84), and 63% (51/81) at 12, 24, 36, and 48 weeks, respectively. The MR rates were 32% (28/88), 36% (29/81), 49% (38/77), and 57% (42/74) at 12, 24, 36, and 48 weeks, respectively. The Phi Coefficient for the association between CHR and MR was 0.6146 ( p < .0001) at 48 weeks. In the subgroup analysis, patients with hydroxyurea resistance or intolerance, and those who were hydroxyurea‐naïve, had similar results in terms of the CHR. In conclusion, CHR and MR were observed to be associated in patients with PV treated with ropeginterferon.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycythemia VeraPolyethylene GlycolsInterferon-alphaHumansMaleFemaleMiddle AgedRecombinant ProteinsInterferon alpha-2AdultProspective StudiesAgedJanus Kinase 2Treatment OutcomeMutation

Stichwörter der Autor:innen

CHRMRassociationpolycythemia veraropeginterferon alfa‐2b

Substanzen

Polyethylene GlycolsInterferon-alphaRecombinant ProteinsInterferon alpha-2peginterferon alfa-2bJanus Kinase 2JAK2 protein, human

Autor:innen und Institutionen

  • Division of Hematology & Medical Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Jeollanam-do, Korea.
  • Division of Hematology-Oncology, Department of Internal Medicine, Institute of Health Science, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea.
  • Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea.
  • Department of Hematology/Oncology, Pusan National University Hospital, Busan, Korea.

Förderung

  • PharmaEssentia, Taiwan

Zitieren

APA

Yoon, S. Y., Yoon, S. S., Yang, D. H., Lee, G. W., Sohn, S. K., Shin, H. J., Bae, S. H., Choi, C. W., Choi, E. J., Cheong, J. W., Bang, S. M., Park, J. S., Oh, S. J., Park, Y., Park, Y. H., & Lee, S. E. (2025). Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective study. International Journal of Cancer, 157(3), 526-533. https://doi.org/10.1002/ijc.35411

Vancouver

Yoon SY, Yoon SS, Yang DH, Lee GW, Sohn SK, Shin HJ, et al. Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective study. International Journal of Cancer. 2025;157(3):526-533. doi:10.1002/ijc.35411

BibTeX
@article{Yoon2025,
  author = {Yoon, Seug Yun and Yoon, Sung-Soo and Yang, Deok-Hwan and Lee, Gyeong-Won and Sohn, Sang Kyun and Shin, Ho-Jin and Bae, Sung Hwa and Choi, Chul Won and Choi, Eun-Ji and Cheong, June-Won and Bang, Soo-Mee and Park, Joon Seong and Oh, Suk Joong and Park, Yong and Park, Young Hoon and Lee, Sung-Eun},
  title = {Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective study},
  journal = {International Journal of Cancer},
  year = {2025},
  volume = {157},
  number = {3},
  pages = {526--533},
  doi = {10.1002/ijc.35411}
}
Kostenlos starten →